Senior MSL Manager – Oncology Launch Leader
Salva questo lavoro e mantieni la tua ricerca organizzata
Crea un account gratuito per salvare lavori, creare avvisi e tornare a questa inserzione dalla tua dashboard.
Continuando accetti i nostri Termini & Informativa sulla privacy.
subrosa Health & Capital group seeks a Senior Medical Science Liaison Manager (F/M/X) to support the expansion of its Medical Affairs presence in Italy, focusing on an oncology launch for RAS-driven cancers. The role emphasizes building scientific relationships with KOLs, HCPs and clinical study sites, leading peer-to-peer exchanges and collaborating cross-functionally to shape launch readiness.
This home-based position offers strategic responsibility and close collaboration with international
#J-18808-Ljbffr-
Senior Medical Science Liaison
3 giorni fa
Novara, Piemonte, Italia subrosa Health & Capital group Tempo pieno🚀 An exciting oncology launch opportunity!Senior Medical Science Liaison Manager (F/M/X) Italy Our client is a pioneering oncology company developing innovative targeted therapies for patients with RAS-driven cancers, which account for approximately 30% of all cancer diagnoses worldwide.With a deep pipeline of RAS(ON) inhibitors, our client is redefining...
-
Senior MSL Manager – Oncology Launch Leader
1 giorno fa
Novara, Piedmont, Italia subrosa Health & Capital group Tempo pienosubrosa Health & Capital group seeks a Senior Medical Science Liaison Manager (F/M/X) to support the expansion of its Medical Affairs presence in Italy, focusing on an oncology launch for RAS-driven cancers. The role emphasizes building scientific relationships with KOLs, HCPs and clinical study sites, leading peer-to-peer exchanges and collaborating...
-
Senior Medical Science Liaison
4 giorni fa
novara, Italia subrosa Health & Capital group Tempo pieno🚀 An exciting oncology launch opportunity! Senior Medical Science Liaison Manager (F/M/X) Italy Our client is a pioneering oncology company developing innovative targeted therapies for patients with RAS-driven cancers, which account for approximately 30% of all cancer diagnoses worldwide. With a deep pipeline of RAS(ON) inhibitors, our client is...